Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | CPA2 | P48052 | 1/20 | 0.48 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24178269 | 1.00 | PTPN1 (0.49) | PTPN1CPA1CPA2CPA4GNPAT | |
| SCHEMBL24178265 | 0.95 | GNPAT (0.52) | PTPN1GNPATMMEANPEPCTSB | |
| SCHEMBL24178266 | 0.95 | GNPAT (0.52) | PTPN1GNPATMMEANPEPCTSB | |
| SCHEMBL24178184 | 0.94 | PTPN1 (0.43) | PTPN1CPA1CPA2CPA4MME | |
| SCHEMBL24178167 | 0.88 | CPA1 (0.52) | CPA1CPA2CPA4GNPATCASP1 | |
| SCHEMBL24178183 | 0.87 | CTSB (0.52) | CPA1CPA2CPA4ANPEPCTSB | |
| SCHEMBL24178171 | 0.87 | CTSB (0.52) | CPA1CPA2CPA4ANPEPCTSB | |
| SCHEMBL24178166 | 0.85 | CTSB (0.56) | CPA1CPA2CPA4CTSBCTSL | |
| SCHEMBL24178185 | 0.83 | SMN1; SMN2 (0.46) | ANPEPCTSBLTA4HBACE1 | |
| SCHEMBL25465177 | 0.83 | CPA1 (0.50) | PTPN1CPA1CPA2CPA4GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | YALE UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220002354-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN PROTEASE INHIBITORS AND ANALOGS THEREOF | YALE UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | LPXN, LAP3, PEPD | PTPN1 2403/4885CPA1 99/4885CPA2 134/4885 |
| US-20220002354-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN PROTEASE INHIBITORS AND ANALOGS THEREOF | LPXN, LAP3, PEPD | PTPN1 2403/4885CPA1 99/4885CPA2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.